1
|
Zhou S, Ding X, Zhang Y, Liu Y, Wang X, Guo Y, Zhang J, Liu X, Gong G, Su Y, Wang L, Zhao M, Hu M. Evaluation of specific RBE in different cells of hippocampus under high-dose proton irradiation in rats. Sci Rep 2024; 14:8193. [PMID: 38589544 PMCID: PMC11001863 DOI: 10.1038/s41598-024-58831-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Accepted: 04/03/2024] [Indexed: 04/10/2024] Open
Abstract
The study aimed to determine the specific relative biological effectiveness (RBE) of various cells in the hippocampus following proton irradiation. Sixty Sprague-Dawley rats were randomly allocated to 5 groups receiving 20 or 30 Gy of proton or photon irradiation. Pathomorphological neuronal damage in the hippocampus was assessed using Hematoxylin-eosin (HE) staining. The expression level of NeuN, Nestin, Caspase-3, Olig2, CD68 and CD45 were determined by immunohistochemistry (IHC). The RBE range established by comparing the effects of proton and photon irradiation at equivalent biological outcomes. Proton20Gy induced more severe damage to neurons than photon20Gy, but showed no difference compared to photon30Gy. The RBE of neuron was determined to be 1.65. Similarly, both proton20Gy and proton30Gy resulted in more inhibition of oligodendrocytes and activation of microglia in the hippocampal regions than photon20Gy and photon30Gy. However, the expression of Olig2 was higher and CD68 was lower in the proton20Gy group than in the photon30Gy group. The RBE of oligodendrocyte and microglia was estimated to be between 1.1 to 1.65. For neural stem cells (NSCs) and immune cells, there were no significant difference in the expression of Nestin and CD45 between proton and photon irradiation (both 20 and 30 Gy). Therefore, the RBE for NSCs and immune cell was determined to be 1.1. These findings highlight the varying RBE values of different cells in the hippocampus in vivo. Moreover, the actual RBE of the hippocampus may be higher than 1.1, suggesting that using as RBE value of 1.1 in clinical practice may underestimate the toxicities induced by proton radiation.
Collapse
Affiliation(s)
- Shengying Zhou
- School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, Shandong, China
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
| | - Xingchen Ding
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
| | - Yiyuan Zhang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
| | - Yuanyuan Liu
- Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China
| | - Xiaowen Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
- Shandong University cancer center, Jinan, 250100, Shandong, China
| | - Yujiao Guo
- Affiliated Hospital of Jining Medical College, Jining, 272067, Shandong, China
| | | | - Xiao Liu
- 960 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Jinan, 250031, Shandong, China
| | - Guanzhong Gong
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
| | - Ya Su
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
| | - Lizhen Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China
| | - Miaoqing Zhao
- Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
| | - Man Hu
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, NO.440 Ji Yan Road, Jinan, 250117, Shandong, China.
| |
Collapse
|
2
|
Ronga MG, Cavallone M, Patriarca A, Leite AM, Loap P, Favaudon V, Créhange G, De Marzi L. Back to the Future: Very High-Energy Electrons (VHEEs) and Their Potential Application in Radiation Therapy. Cancers (Basel) 2021; 13:4942. [PMID: 34638424 PMCID: PMC8507836 DOI: 10.3390/cancers13194942] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 09/27/2021] [Accepted: 09/28/2021] [Indexed: 12/14/2022] Open
Abstract
The development of innovative approaches that would reduce the sensitivity of healthy tissues to irradiation while maintaining the efficacy of the treatment on the tumor is of crucial importance for the progress of the efficacy of radiotherapy. Recent methodological developments and innovations, such as scanned beams, ultra-high dose rates, and very high-energy electrons, which may be simultaneously available on new accelerators, would allow for possible radiobiological advantages of very short pulses of ultra-high dose rate (FLASH) therapy for radiation therapy to be considered. In particular, very high-energy electron (VHEE) radiotherapy, in the energy range of 100 to 250 MeV, first proposed in the 2000s, would be particularly interesting both from a ballistic and biological point of view for the establishment of this new type of irradiation technique. In this review, we examine and summarize the current knowledge on VHEE radiotherapy and provide a synthesis of the studies that have been published on various experimental and simulation works. We will also consider the potential for VHEE therapy to be translated into clinical contexts.
Collapse
Affiliation(s)
- Maria Grazia Ronga
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
- Thales AVS Microwave & Imaging Sub-Systems, 78141 Vélizy-Villacoublay, France
| | - Marco Cavallone
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
| | - Annalisa Patriarca
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
| | - Amelia Maia Leite
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
- INSERM LITO U1288, Campus Universitaire, Institut Curie, PSL Research University, University Paris Saclay, 91898 Orsay, France
| | - Pierre Loap
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
| | - Vincent Favaudon
- INSERM U 1021-CNRS UMR 3347, Campus Universitaire, Institut Curie, PSL Research University, University Paris Saclay, 91898 Orsay, France;
| | - Gilles Créhange
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
| | - Ludovic De Marzi
- Centre de Protonthérapie d’Orsay, Department of Radiation Oncology, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France; (M.G.R.); (M.C.); (A.P.); (A.M.L.); (P.L.); (G.C.)
- INSERM LITO U1288, Campus Universitaire, Institut Curie, PSL Research University, University Paris Saclay, 91898 Orsay, France
| |
Collapse
|
3
|
Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives. Cancers (Basel) 2021; 13:cancers13153744. [PMID: 34359644 PMCID: PMC8345082 DOI: 10.3390/cancers13153744] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 07/23/2021] [Accepted: 07/23/2021] [Indexed: 01/15/2023] Open
Abstract
Simple Summary Hodgkin lymphoma (HL) is a highly curable disease; proton therapy for mediastinal HL irradiation might theoretically reduce late toxicities compared with classical radiotherapy techniques. However, optimal patient selection for this technique is subject to debate. While implementation at a larger scale of proton therapy for HL may face organizational, political, and societal challenges, new highly effective systematic drugs are being widely evaluated for this disease. Abstract Consolidative radiation therapy for early-stage Hodgkin lymphoma (HL) improves progression-free survival. Unfortunately, first-generation techniques, relying on large irradiation fields, were associated with an increased risk of secondary cancers, and of cardiac and lung toxicity. Fortunately, the use of smaller target volumes combined with technological advances in treatment techniques currently allows efficient organs-at-risk sparing without altering tumoral control. Recently, proton therapy has been evaluated for mediastinal HL treatment due to its potential to significantly reduce the dose to organs-at-risk, such as cardiac substructures. This is expected to limit late radiation-induced toxicity and possibly, second-neoplasm risk, compared with last-generation intensity-modulated radiation therapy. However, the democratization of this new technique faces multiple issues. Determination of which patient may benefit the most from proton therapy is subject to intense debate. The development of new effective systemic chemotherapy and organizational, societal, and political considerations might represent impediments to the larger-scale implementation of HL proton therapy. Based on the current literature, this critical review aims to discuss current challenges and controversies that may impede the larger-scale implementation of mediastinal HL proton therapy.
Collapse
|
4
|
The Significance of Redox Biomarkers in the Evaluation of the Antioxidant Profile In Vitro and In Vivo. Antioxidants (Basel) 2021; 10:antiox10050805. [PMID: 34069525 PMCID: PMC8160960 DOI: 10.3390/antiox10050805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Accepted: 05/17/2021] [Indexed: 11/17/2022] Open
Abstract
The present Special Issue of Antioxidants, entitled The Significance of Redox Biomarkers in the Evaluation of the Antioxidant Profile In Vitro and In Vivo, ten research articles emphasize the significance of adopting reliable redox biomarkers to determine the antioxidant activities of bioactive compounds in vitro and to assess blood and tissue redox status in vivo [...].
Collapse
|
5
|
Leduc A, Chaouni S, Pouzoulet F, De Marzi L, Megnin-Chanet F, Corre E, Stefan D, Habrand JL, Sichel F, Laurent C. Differential normal skin transcriptomic response in total body irradiated mice exposed to scattered versus scanned proton beams. Sci Rep 2021; 11:5876. [PMID: 33712719 PMCID: PMC7955113 DOI: 10.1038/s41598-021-85394-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Accepted: 02/10/2021] [Indexed: 12/13/2022] Open
Abstract
Proton therapy allows to avoid excess radiation dose on normal tissues. However, there are some limitations. Indeed, passive delivery of proton beams results in an increase in the lateral dose upstream of the tumor and active scanning leads to strong differences in dose delivery. This study aims to assess possible differences in the transcriptomic response of skin in C57BL/6 mice after TBI irradiation by active or passive proton beams at the dose of 6 Gy compared to unirradiated mice. In that purpose, total RNA was extracted from skin samples 3 months after irradiation and RNA-Seq was performed. Results showed that active and passive delivery lead to completely different transcription profiles. Indeed, 140 and 167 genes were differentially expressed after active and passive scanning compared to unirradiated, respectively, with only one common gene corresponding to RIKEN cDNA 9930021J03. Moreover, protein-protein interactions performed by STRING analysis showed that 31 and 25 genes are functionally related after active and passive delivery, respectively, with no common gene between both types of proton delivery. Analysis showed that active scanning led to the regulation of genes involved in skin development which was not the case with passive delivery. Moreover, 14 ncRNA were differentially regulated after active scanning against none for passive delivery. Active scanning led to 49 potential mRNA-ncRNA pairs with one ncRNA mainly involved, Gm44383 which is a miRNA. The 43 genes potentially regulated by the miRNA Gm44393 confirmed an important role of active scanning on skin keratin pathway. Our results demonstrated that there are differences in skin gene expression still 3 months after proton irradiation versus unirradiated mouse skin. And strong differences do exist in late skin gene expression between scattered or scanned proton beams. Further investigations are strongly needed to understand this discrepancy and to improve treatments by proton therapy.
Collapse
Affiliation(s)
- Alexandre Leduc
- Normandie Univ, UNICAEN, UNIROUEN, ABTE-EA4651, ToxEMAC, Cancer Centre François Baclesse, 14000, Caen, France
| | - Samia Chaouni
- Normandie Univ, UNICAEN, UNIROUEN, ABTE-EA4651, ToxEMAC, Cancer Centre François Baclesse, 14000, Caen, France
| | - Frédéric Pouzoulet
- Institut Curie, RadeXp Platform, centre universitaire, 91405, Orsay, France
| | - Ludovic De Marzi
- Institut Curie, PSL Research University, University Paris Saclay, Laboratoire d'Imagerie Translationnelle en Oncologie, INSERM, 91401, Orsay, France
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - Frédérique Megnin-Chanet
- INSERM U1196/UMR9187 CMIB, University Paris-Saclay, Institut Curie-Recherche, bât. 112, rue H. Becquerel, 91405, Orsay, France
| | - Erwan Corre
- CNRS, Sorbonne Université, R2424, ABiMS platform, Station Biologique, 29680, Roscoff, France
| | - Dinu Stefan
- Normandie Univ, UNICAEN, UNIROUEN, ABTE-EA4651, ToxEMAC, Cancer Centre François Baclesse, 14000, Caen, France
- Radiotherapy Department, Cancer Centre François Baclesse, 14000, Caen, France
| | - Jean-Louis Habrand
- Normandie Univ, UNICAEN, UNIROUEN, ABTE-EA4651, ToxEMAC, Cancer Centre François Baclesse, 14000, Caen, France
- Radiotherapy Department, Cancer Centre François Baclesse, 14000, Caen, France
| | - François Sichel
- Normandie Univ, UNICAEN, UNIROUEN, ABTE-EA4651, ToxEMAC, Cancer Centre François Baclesse, 14000, Caen, France
| | - Carine Laurent
- Normandie Univ, UNICAEN, UNIROUEN, ABTE-EA4651, ToxEMAC, Cancer Centre François Baclesse, 14000, Caen, France.
- SAPHYN/ARCHADE (Advanced Resource Centre for HADrontherapy in Europe), Cancer Centre François Baclesse, 14000, Caen, France.
| |
Collapse
|